BridgeBio Oncology Therapeutics, Inc. Common Stock

Shares of BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) are trading at $7.40. The technical outlook is "Strong Sell" based on moving average alignment, RSI, and MACD signals. This is driven by negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, BBOT trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jun 26, 2026.